Safety Evaluation of a Q-fever Vaccine, NDBR 105

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

June 30, 2014

Conditions
Q Fever
Interventions
BIOLOGICAL

Q Fever Vaccine (NDBR 105

Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.

Trial Locations (1)

21702

U.S. Army Medical Research Institute of Infectious Diseases, Fort Deterick

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT00584454 - Safety Evaluation of a Q-fever Vaccine, NDBR 105 | Biotech Hunter | Biotech Hunter